CALGB 40302: Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: A double-blinded, placebo-controlled, randomized phase III study Meeting Abstract
| Authors: | Burstein, H. J.; Barry, W. T.; Cirrincione, C.; Chew, H. K.; Tolaney, S.; Lake, D.; Pluard, T.; Blackwell, K.; Winer, E. P.; Hudis, C. A. |
| Abstract Title: | CALGB 40302: Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: A double-blinded, placebo-controlled, randomized phase III study |
| Meeting Title: | 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 70 |
| Issue: | 24 Suppl. |
| Meeting Dates: | 2010 Dec 9-12 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2010-12-15 |
| Language: | English |
| ACCESSION: | WOS:000209695801407 |
| DOI: | 10.1158/0008-5472.sabcs10-pd05-01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PD05-01 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
